| Document |
Document Title |
|
WO/2023/282138A1 |
The present disclosure provides an organic metal complex characterized by being represented by general formula (1). In general formula (1), M represents a metal atom and is selected from Ir, Pt, Os, Rh, Pd and Ru; R1 to R8 independently ...
|
|
WO/2023/281046A1 |
The present invention provides novel bispidone ligands and transition metal complexes thereof, especially iron and manganese complexes thereof. Furthermore, the present invention also relates to the use of said bispidone ligands and comp...
|
|
WO/2023/275422A1 |
Disclosed are: a mononuclear Ru(III) compound comprising two molecules of 2,2'-biimidazole as ligands; a method for obtaining same; and the therapeutic use thereof, preferably as an anti-carcinogenic agent. The cancer may be breast cance...
|
|
WO/2023/276543A1 |
The problem to be addressed by the present invention is to provide a toner, ink, printed matter, paint, coating, plastic, fiber, film, resist for black matrices, resist for photo spacers, and cured products of the preceding, by using, as...
|
|
WO/2023/276544A1 |
The problem to be solved by the present invention is to decolorize and solubilize a metal complex by easy methods using non-petroleum raw materials, thereby providing recyclable toners, inks, printed matter, paints, coatings, plastics, f...
|
|
WO/2022/269245A1 |
The specification describes hydrosiylation catalysts of Formula (Ia), (Ib), (Ic) and (Id). These catalysts show accelerated hydrosilylation activity in the presence of UV. Also described is the use of such catalysts in a hydrosilylation ...
|
|
WO/2022/266768A1 |
There is provided an iron-based complex of formula (IA) or (IB) or a solvate thereof (IA) (IB). The iron-based complex can be used for catalyzing a hydrosilylation reaction, such as the hydrosilylation of a ketone or an aldehyde. Also pr...
|
|
WO/2022/267941A1 |
Disclosed are an organometallic iridium compound and an application thereof. The organometallic iridium compound has the general formula of Ir(La)(Lb)(Lc), wherein La is the structure shown in formula (1) and Lb is the structure shown in...
|
|
WO/2022/262309A1 |
The present invention relates to an organometallic iridium compound and an application thereof. The organometallic iridium compound has a general formula of Ir(La)(Lb)(Lc), wherein La is the structure shown in formula (1), and Lb is the ...
|
|
WO/2022/263800A1 |
The invention relates to a process for synthesising organic molecules. The invention provides a process for forming an sp2-sp3 carbon-carbon bond between a first compound comprising a substituted or unsubstituted aromatic group and a sec...
|
|
WO/2022/262308A1 |
The present invention relates to a heterocyclic modified platinum complex containing an ONCN tetradentate ligand, which has the structure as shown in chemical formula (I). The described complex is used in organic light-emitting diodes, h...
|
|
WO/2022/262300A1 |
Disclosed in the present invention are a neutral iridium complex containing a biphenyl derivative ligand, a preparation method therefor and the application thereof in the preparation of an organic electronic device, in particular an orga...
|
|
WO/2022/261770A1 |
The present invention relates to a combination comprising a neurotensin receptor binding compound and FOLFIRINOX for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.
|
|
WO/2022/262662A1 |
The present invention relates to an organometallic compound having a general formula Ir(La)(Lb)(Lc), and an application thereof. La is a structure represented by formula (1), and Lb is a structure represented by formula (2). The compound...
|
|
WO/2022/264759A1 |
The present disclosure provides an organic compound represented by the formula: M(L1)n(L2)m (wherein M represents a metal atom; n+m = 3; and n ≧ 1). M(L1) is represented by any one of general formulae [1] to [3], and M(L2) is represent...
|
|
WO/2022/256897A1 |
The present disclosure is directed to chelated nutrients having a structure [M(Ligand 1)(Ligand 2)]2Y, wherein: M is a metal selected from the group consisting of Cu, Mn, Zn, Co, Ni, Mg, Ca and Fe; Ligand 1 is glutamic acid; Ligand 2 is ...
|
|
WO/2022/253231A1 |
Platinum (II) complexes ( "Pt (II) complexes" ) that can emit in the red and/or deep red regions and methods of making and using thereof are described. These Pt (II) complexes can have dinuclearity with close Pt-Pt contact and close inte...
|
|
WO/2022/253221A1 |
Described herein are compounds containing palladium (II), as the central metal atom, and tetradentate [N^C^C^N] ligands. The compounds are charge neutral, and feature a donor-acceptor structure where a pendant substituted amino group (su...
|
|
WO/2022/256525A1 |
In an embodiment, the present disclosure pertains to a composition having a cation and an anion. In some embodiments, a base is incorporated into the anion, and the cation and the anion form a bifunctional catalyst. In some embodiments, ...
|
|
WO/2022/252360A1 |
Disclosed are a nickel polysulfide-mercaptobenzimidazole coordination compound and a preparation method therefor and an application thereof. The preparation method comprises the following steps: (1) dissolving a nickel salt and 2-mercapt...
|
|
WO/2022/253220A1 |
Described herein are dinuclear platinum (II) emitter complexes and their methods of making and using thereof. The design of the dinuclear platinum (II) emitters results in short radiative lifetimes and high quantum yields. The dinuclear ...
|
|
WO/2022/250525A1 |
The present invention relates to palladium containing compounds for use in light-activated anticancer treatment. Such molecules are bis-cyclometalated palladium complexes that, once in biological medium or blood, may self-assemble into n...
|
|
WO/2022/249178A1 |
Provided herein a polyoxometalate compound represented by formula (I): (Q)n[XMaMbMc(La)(Lb)(Lc)W9O37] (I) or a solvate thereof; and a method of electrocatalytic reduction of carbon dioxide (CO2) using the polyoxometalate compound.
|
|
WO/2022/250044A1 |
Provided is an iridium complex compound represented by formula (1). The iridium complex compound has high solubility in solvents, exhibits excellent luminous efficiency when used in an organic EL element, and achieves an excellent operat...
|
|
WO/2022/242264A1 |
The present invention relates to an organometallic iridium compound and an application thereof. The organometallic iridium compound has a structure that is represented by formula (1). The compound provided in the present invention has th...
|
|
WO/2022/240841A1 |
The present disclosure concerns cucurbit[n]uril (CB) complexes of cucurbit[8]uril (CB[8]) and/or cucurbit[7]uril (CB[7]) that secure or host platinum conjugated terpyridines. The platinum center can further secure a protein through the t...
|
|
WO/2022/238163A1 |
The present invention relates to chemotherapeutic compounds and, in particular, metal complexes used for the purpose. Furthermore, it also relates to an innovative process for the preparation of said compounds and their therapeutic use.
|
|
WO/2022/233178A1 |
The present invention relates to an organometallic compound and an application thereof. The organometallic compound has a general formula of Ir(La)(Lb)(Lc), wherein La has a structure represented by formula (1). The compound provided by ...
|
|
WO/2022/225313A1 |
The present invention relates to: a transition metal complex having a bidentate ligand which includes pyrazole, triazole, tetrazole, oxadiazole, thiadiazole, or the like, wherein the transition metal complex can be used as an electron tr...
|
|
WO/2022/223011A1 |
The present invention provides a high radiation rate platinum complex based on 1,8-substituted carbazole and an application thereof. The luminescent material of the present invention can efficiently control the excited state properties o...
|
|
WO/2022/222210A1 |
Disclosed in the present invention are an organo-transition metal compound and a preparation method therefor, and a method for forming a transition metal-containing film. The structural formula of the organo-transition metal compound is ...
|
|
WO/2022/220153A1 |
Provided is a thin film-forming feedstock, for use in atomic layer deposition, that contains a ruthenium compound represented by general formula (1) below. (In formula (1), R1, R2, R3, R4, R5, and R6 each independently represent a hydrog...
|
|
WO/2022/217255A1 |
Novel compounds and compositions including the same and methods of manufacturing and using the same, particularly for use as an anticancer/antitumor drug and/or for oncological indications. Novel compounds comprising or formed as conjuga...
|
|
WO/2022/206684A1 |
Provided are a series of Se-containing pyrazine compounds and an application thereof. Specifically disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/211647A1 |
A method of obtaining iron chelate from hydrated iron(III) sulphate, which includes the following steps: a solution consisting of alanine and deionized water is prepared at 20° C in a weight ratio of 1: 5.2, then the temperature is rais...
|
|
WO/2022/204065A1 |
The present application describes novel Fe(III) macrocyclic complexes that have hydroxy pendants with a third anionic ancillary group for improved MR imaging in vivo. The complexes have the following general structure:(I) or (II) where h...
|
|
WO/2022/191601A1 |
The present invention relates to an organic electro luminescence device. The organic electro luminescence device comprises a light-emitting layer including an iridium complex of a specific structure and a host, thereby having a low drivi...
|
|
WO/2022/190844A1 |
The present invention is a chemical vapor deposition starting material for producing a ruthenium thin film or a ruthenium compound thin film by chemical vapor deposition, said chemical vapor deposition starting material being characteriz...
|
|
WO/2022/191609A1 |
The present invention relates to a novel iridium complex and an organic electroluminescent device comprising same and, specifically, to a novel iridium complex that can be used as a blue phosphorescent dopant of a light-emitting layer an...
|
|
WO/2022/187311A1 |
The present disclosure relates in part to sterically hindered N-aliphatic N-heterocyclic carbene (NHC) ligands, which are readily synthetically available from inexpensive starting materials. The present disclosure further relates to NHC ...
|
|
WO/2022/183467A1 |
A heteroaromatic ring tridentate pyridine imine iron complex, a preparation method therefor, and an application thereof in the catalysis of conjugated diene polymerization. The present invention relates to the field of the catalytic poly...
|
|
WO/2022/178840A1 |
A compound for measurement of thiopurine pathway directed systems imaging and therapy including a chelator and a thiopurine ligand is provided. A method of synthesizing the compound is also provided, and the compound may be further prepa...
|
|
WO/2022/175111A1 |
The invention relates to a process for preparing compounds of the general formula MAYn(AzuH) (I), where MA = alkali metal, Y = neutral ligand, n = 0, 1, 2, 3 or 4. AzuH is azulene (bicyclo[5.3.0]decapentaene) or an azulene derivative tha...
|
|
WO/2022/170893A1 |
A terpyridine iron/ruthenium complex containing nitrogen mustard, a synthesis method and an application. The structural formula of the terpyridine iron/ruthenium complex containing nitrogen mustard is as shown below, wherein M is one of ...
|
|
WO/2022/166889A1 |
The present application provides a compound of general formula (I), capable of being used for an organic electroluminescent device as a guest material of a light-emitting layer. The compound contains a structure in which a natural hetero...
|
|
WO/2022/167909A1 |
Provided is a compound comprising a chelated platinum ion, wherein the platinum ion is chelated with a chelating agent and the chelating agent is a sodium salt of, a potassium salt of, or an ammonium salt of EDTA, DTPA, GLDA, MGDA, HEDTA...
|
|
WO/2022/167944A1 |
Embodiments in accordance with the present invention encompass an organorutheniumcompound of the formula I:(I)wherein X, Y, L1, L2, L3, R1 and R2 are as defined herein. Also disclosed herein are the use of organoruthenium compound of the...
|
|
WO/2022/161453A1 |
The present invention provides an organic metal complex and an organic optoelectronic component comprising same, specifically, an organic electroluminescent diode, where the structure of the organic metal complex is as represented by for...
|
|
WO/2022/164086A1 |
Provided is an organometallic complex which contributes to substantial improvements in the luminous color and luminous efficiency of an organic electroluminescent device. An organic electroluminescent device according to the present inve...
|
|
WO/2022/163736A1 |
[Problem] To provide an azo iron complex dye which does not contain harmful heavy metals, exhibits sufficient solubility in organic solvents for practical use, and exhibits a good black color. [Solution] This azo iron complex dye contain...
|
